STOK Stock Forecast & Price Target

Stoke Therapeutics Inc. has shown promising advancements in its development of zorevunersen for Dravet syndrome, with positive outcomes from ongoing studies indicating meaningful seizure reductions and statistical significance in key measurements. The company's financial performance reflects this progress, with a substantial revenue increase from $36.6 million in FY24 to $184 million in FY25, largely attributed to a $165 million upfront payment from its collaboration with Biogen. Despite increased R&D and operating expenses, the company's ability to enroll patients rapidly in the phase III EMPEROR study adds to the positive outlook, positioning Stoke Therapeutics favorably within the biotechnology sector.

Stoke Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from potential patent issues that could undermine the company's market success and valuation. The company reported a net loss of $6.9 million for the year 2025, with an earnings per share of -$0.12, reflecting ongoing financial instability and a prolonged path to profitability. Additionally, Stoke must navigate industry-standard challenges, such as clinical and regulatory uncertainties, which may hinder the successful development and commercialization of its drug candidates, along with the need for further capital that could dilute existing shareholder equity.